Evaxion Biotech A/S
EVAX · NASDAQ
Bulios Fair Price
$3.56
16.0% upside
Current Price
$3.07
According to Bulios Fair Price, EVAX is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Evaxion Biotech A/S (EVAX) is a biotechnology company specializing in the development of immunotherapeutic treatment approaches in oncology and infectious diseases. The company focuses on developing personalized vaccines and treatment methods based on the analysis of patients' immune responses. Evaxion Biotech aims to innovate in diagnostics and therapy to enhance a patient's ability to fight against cancer and infections. Their approaches are based on utilizing modern technologies and data analytics. Shares of Evaxion Biotech A/S (EVAX) can be an interesting choice for investors tracking the biotechnology sector and innovations in the field of immunotherapy.
Sector
Healthcare
Industry
Biotechnology
CEO
Helen Katrina Tayton-Martin
Employees
46
Headquarters
Horsholm
Upcoming events
Earnings
Upcoming earnings report